Publication Name	World Journal of Gastroenterology
Manuscript ID	1173
Country	China

Received	2012-11-17 20:59
Peer-Review Started	2012-11-20 11:38
To Make the First Decision	2013-01-05 11:50
Return for Revision	2013-01-06 10:11
Revised	2013-01-24 14:28
Second Decision	2013-03-28 17:21
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-03-29 12:04
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-04-11 13:11
Typeset the Manuscript	2013-06-07 09:27
Publish the Manuscript Online	2013-06-14 23:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Autobiography
Article Title	Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis
Manuscript Source	Invited Manuscript
All Author List	Guo-Cai Lv, Jin-Mei Yao, Yi-Da Yang, Lin Zheng, Ji-Fang Sheng, Yu Chen and Lan-Juan Li
Funding Agency and Grant Number	Funding Agency Grant Number China National Science and Technology Major Project 2010ZB063 Health Department of Zhejiang Province, China 2010KYA067
Corresponding Author	Lan-Juan Li, MD, PhD, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital of Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. ljli@mail.hz.zj.cn
Key Words	Liver cirrhosis; Lamivudine; Adefovir dipivoxil; Efficacy; Alanine transaminase
Core Tip	Present treatment guidelines advocate oral nucleos(t)ide analogues in decompensated chronic hepatitis B (CHB) patients. Studies with lamivudine (LAM) have demonstrated decreased mortality and improved liver function in CHB decompensated patients. However, LAM resistance mutations emerging during monotherapy can negate therapeutic benefit. Adefovir dipivoxil had no cross resistance with LAM. Consistent with outcomes in patients with LAM-resistance, no patient in de novo combination therapy group showed detectable resistance up to 144 wk in this study. The de novo combination therapy markedly improved liver function, reduced Child-Turcotte Pugh and Model for End-Stage Liver Disease scores in hepatitis B virus-related decompensated cirrhosis patients.
Publish Date	2013-06-14 23:10
Citation	Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(22): 3481-3486
URL	http://www.wjgnet.com/1007-9327/full/v19/i22/3481.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i22.3481

Full Article (PDF)	WJG-19-3481.pdf
Manuscript File	1173-Review.doc
Answering Reviewers	1173-Answering reviewers.doc
Copyright License Agreement	1173-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	1173-Language cetificate.pdf
Peer-review Report	1173-Peer review.pdf
Scientific Editor Work List	1173-Scientific editor work list.doc